<DOC>
	<DOCNO>NCT00012298</DOCNO>
	<brief_summary>Phase I/II trial study effectiveness combine radiolabeled monoclonal antibody therapy rituximab without filgrastim interleukin-11 treating patient relapse refractory non-Hodgkin 's lymphoma . Radiolabeled monoclonal antibody locate cancer cell deliver cancer-killing substance without harm normal cell . Biological therapy filgrastim interleukin-11 use different way stimulate immune system stop cancer cell grow .</brief_summary>
	<brief_title>Radiolabeled Monoclonal Antibody Plus Rituximab With Without Filgrastim Interleukin-11 Treating Patients With Relapsed Refractory Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose ( MTD ) yttrium Y 90 ibritumomab tiuxetan ( IDEC-90Y2B8 ) administer rituximab without filgrastim ( G-CSF ) interleukin-11 ( IL-11 ) patient relapse low-grade follicular CD20+ non-Hodgkin 's lymphoma . ( Phase I ) II . Determine toxicity regimen patient . III . Determine response rate patient treat regimen . IV . Compare tumor normal organ dosimetry positron emission tomography computerize tomography scan , subsequent tumor response , normal organ toxicity utilize indium In 111 ibritumomab tiuxetan radioimmunoconjugate scan IDEC-90Y2B8 dose patient . ( Phase I ) V. Determine immune response regimen , term human anti-mouse human anti-chimeric antibody formation , patient . ( Phase I ) VI . Determine whether G-CSF IL-11 ameliorate effect MTD IDEC-90Y2B8 bone marrow function patient . ( Phase I ) VII . Determine progression-free survival 3 year . ( Phase II ) OUTLINE : PHASE I : Patients receive rituximab IV day 1 8 , indium In 111 ibritumomab tiuxetan IV 10 minute day 1 ( radioimaging ) , IDEC-90Y2B8 IV 10 minute day 8 . Treatment repeat 24-36 week later total 2 course absence disease progression unacceptable toxicity . Once maximum tolerate dose ( MTD ) IDEC-90Y2B8 determine , patient also receive filgrastim ( G-CSF ) subcutaneously ( SC ) daily begin absolute neutrophil count le 1,500/mm3 continue blood count recover . Patients also receive interleukin-11 ( IL-11 ) SC begin platelet count le 75,000/mm^3 continue blood count recover . Patients undergo PBSC transplantation marrow recovery inadequate . Cohorts 3-6 patient receive escalate dos IDEC-90Y2B8 MTD determine . The MTD define dose precede least 2 6 patient experience dose-limiting toxicity . Once MTD determine , additional patient accrue determine MTD radioimmunotherapy addition prophylactic cytokine , G-CSF IL-11 . PHASE II : Patients receive rituximab , indium In 111 ibritumomab tiuxetan , IDEC-90Y2B8 IV determine MTD phase I . Treatment repeat 24-36 week later total 2 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 1 year , every 4 month 1 year , every 6 month 1 year , annually 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Oprelvekin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Histologically proven relapsed refractory lowgrade follicular CD+ nonHodgkin lymphoma , include 1 following : Small lymphocytic lymphoma Lymphoplasmacytoid lymphoma Follicular center lymphoma ( grade I , II , III ) Extranodal marginal zone Bcell lymphoma Nodal marginal zone Bcell lymphoma Splenic marginal zone Bcell lymphoma ( monocytoid Bcell lymphoma ) Less 25 % bone marrow involvement cellular marrow lymphoma bilateral bone marrow aspirate biopsy ECOG performance status 02 Bidimensionally measurable disease least 1 lesion &gt; = 2 cm great diameter No prior myeloablative therapy autologous allogeneic bone marrow transplantation peripheral blood stem cell support No concurrent corticosteroid therapy , except prednisone ( equivalent ) adrenal failure &lt; 20mg prednisone daily No prior external beam radiotherapy &gt; 25 % active bone marrow More 4 week since prior surgery diagnostic surgery No concurrent myelosuppressive antineoplastic agent No prior radioimmunotherapy , include yttrium Y 90 ibritumomab tiuxetan iodine I 131 monoclonal antibody tositumomab Lym1 No CNS lymphoma No myelodysplastic syndrome marrow chromosomal change suggest myelodysplasia No HIV AIDSrelated lymphoma No pleural effusion ascites lymphoma cell No active infection No serious nonmalignant disease would preclude study participation No active primary malignancy No known human antimouse human antichimeric antibody No prior skin rash ( e.g. , StevensJohnsons syndrome toxic epidermal necrolysis ) rituximab therapy Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Absolute neutrophil count &gt; = 1,500/mm^3 Platelet count &gt; = 150,000/mm^3 Total lymphocyte count &lt; 5,000/mm^3 patient small lymphocytic lymphoma Bilirubin = &lt; 2 mg/dL Creatinine = &lt; 2 mg/dL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>